Perspective Therapeutics holder sells 35,769 shares

A 10% owner affiliated with Lantheus reported selling 35,769 CATX shares at about $3.12, retaining over 11.5 million shares indirectly.

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. (CATX) had a significant shareholder, Lantheus Holdings, Inc., report the sale of 35,769 shares of common stock on September 1, 2026 in a sale transaction. The weighted average sale price was $3.1193 per share, with individual trades between $3.08 and $3.165 per share.

After this transaction, an affiliated entity, Lantheus Alpha Therapy, LLC, directly held 11,563,425 shares of CATX common stock, and Lantheus Holdings may be deemed to have indirect beneficial ownership of those shares. No Rule 10b5-1 trading plan is reported for this sale.

Insider Trade Summary

Net Seller: 35,769 shares

Net Sell 1 txn

Insider Lantheus Holdings, Inc.

Role 10% Owner

Sold 35,769 shs ($112K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	35,769	$3.1193	$112K

Holdings After Transaction: Common Stock — 11,563,425 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
2. F2. Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

Key Figures

Shares sold: 35,769 shares Weighted average sale price: $3.1193 per share Sale price range: $3.08 to $3.165 per share +2 more

5 metrics

Shares sold 35,769 shares Common stock sale reported for September 1, 2026

Weighted average sale price $3.1193 per share Average price for the 35,769 CATX shares sold

Sale price range $3.08 to $3.165 per share Range of individual trade prices within the reported sale

Shares held after transaction 11,563,425 shares CATX common shares directly held by Lantheus Alpha Therapy, LLC after the sale

Net shares sold 35,769 shares Net change from this filing’s reported transactions

Key Terms

weighted average price, indirect beneficial ownership, ten percent owner

3 terms

weighted average price financial

"The price reported ... is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect beneficial ownership regulatory

"may be deemed to have indirect beneficial ownership of the shares"

ten percent owner regulatory

"identified as a more than ten percent owner of Perspective Therapeutics"

FAQ

What insider transaction did CATX disclose involving Lantheus Holdings?

CATX disclosed that an affiliate of Lantheus Holdings, Inc. sold 35,769 shares of Perspective Therapeutics common stock on September 1, 2026. The transaction was reported as a sale of common stock by a more than ten percent beneficial owner.

At what price were the CATX shares sold in this Form 4 filing?

The filing reports a weighted average sale price of $3.1193 per share for CATX common stock. A footnote explains the shares were sold in multiple transactions at prices ranging from $3.08 to $3.165 per share, inclusive.

How many CATX shares does the Lantheus affiliate hold after this transaction?

After the reported sale, 11,563,425 CATX common shares are directly held by Lantheus Alpha Therapy, LLC. Lantheus Holdings, Inc. may be deemed to have indirect beneficial ownership of these shares under SEC rules.

Who is the reporting person in the CATX Form 4 and what is their status?

The reporting person is Lantheus Holdings, Inc., identified as a more than ten percent owner of Perspective Therapeutics, Inc. The securities are directly held by its wholly owned indirect subsidiary, Lantheus Alpha Therapy, LLC.

Was the CATX insider sale made under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 trading plan for this transaction, and the footnotes do not describe the sale as being made pursuant to any such pre-arranged trading plan.

Is the price in the CATX Form 4 a single trade price or an average?

The reported price of $3.1193 per share is a weighted average price. A footnote states the shares were sold in multiple transactions with prices ranging from $3.08 to $3.165 per share and that detailed trade data is available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:03 PM Accepted by SEC EDGAR 09/03/2026 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lantheus Holdings, Inc.

(Last) (First) (Middle)

201 BURLINGTON ROAD, SOUTH BUILDING

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S		35,769	D	$3.1193(1)	11,563,425	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

2. Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

	/s/ Eric M. Green, Vice President, Deputy General Counsel and Assistant Corporate Secretary	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)